Digest Network Come funziona
Network
/
Società
Cu
Non verificato

Curium

Di cosa scriviamo

Annunci EconomiciFarmaceuticaManagement/Organizzazione AziendaleMedicina Salute Benessere

22 comunicati stampa

Guarda tutti i comunicati
14/09/2026
Farmaceutica
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
10/08/2026
Farmaceutica
Medicina Salute Benessere
Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
03/08/2026
Farmaceutica
Curium Announces Definitive Agreement to Merge with Lantheus
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
18/06/2026
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Court victory paves the way for Curium’s plans to provide targeted radioligand therapy to U.S. patients with GEP-NETs
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
11/06/2026
Farmaceutica
Management/Organizzazione Aziendale
Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
31/05/2026
Farmaceutica
Curium Announces a Strategic Investment of Over €32 million in Saclay, France
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
26/02/2026
Farmaceutica
Medicina Salute Benessere
Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
03/02/2026
Farmaceutica
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
07/01/2026
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Curium’s Investigational New Drug Application Accepted by Center for Drug Evaluation in China
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
22/12/2025
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0